We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ABSCF market cap is 65.61M. The company's latest EPS is EUR -0.1504 and P/E is -9.18.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 1.58M | 1.61M | 958k | 970k | 1.07M |
| Operating Income | -14.75M | -13.81M | -15.94M | -13.43M | -6.08M |
| Net Income | -15.05M | -14.46M | -13.62M | -11.99M | -7.83M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 29.69M | 21.27M | 23.84M | 25.5M | 23.18M |
| Total Liabilities | 49.24M | 44.47M | 59.51M | 46.51M | 46.93M |
| Total Equity | -19.55M | -23.2M | -35.67M | -21.01M | -23.75M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -13.51M | -17.18M | -17.47M | -16.87M | 525k |
| Investing | -277k | -590k | -360k | -614k | -136k |
| Financing | 28.73M | 5.84M | 16.39M | 16.27M | 1.53M |
| Market Cap | 65.61M |
| Price to Earnings Ratio | -9.18 |
| Price to Sales Ratio | 66.99 |
| Price to Cash Ratio | 9 |
| Price to Book Ratio | -3.03 |
| Dividend Yield | - |
| Shares Outstanding | 52.07M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 18.87% |
| 52 Week High | 1.60 |
| 52 Week Low | 0.80 |
| Spread (Intraday) | 0 (0%) |
| Company Name | AB Science Paris (CE) |
| Address |
3 avenue george v paris, paris 75008 |
| Website | https://www.ab-science.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
